Table 1.
Baseline characteristics of pediatric patients with malignant brain tumors (N = 81).
| Characteristic* | Age subgroups | Total (N = 81) | |
|---|---|---|---|
| Children (<13 years of age)(n = 40) | Adolescents (13–17 years of age)(n = 41) | ||
| a Median Age, years (range) | 10 (3–12) | 15 (13–17) | 13 (3–17) |
| Sex, n (%) | |||
| Male | 29 (73) | 25 (61) | 54 (67) |
| Female | 11 (28) | 16 (39) | 27 (33) |
| Region, n (%) | |||
| United States | 28 (70) | 31 (76) | 59 (73) |
| EMEA† | 12 (30) | 9 (22) | 21 (26) |
| Japan | 0 | 1 (2) | 1 (1) |
| Newly diagnosed, n (%) | 18 (45) | 23 (56) | 41 (51) |
| Anaplastic astrocytoma‡ | 6 (15) | 2 (5) | 8 (10) |
| Glioblastoma‡ | 12 (30) | 20 (49) | 32 (40) |
| High-grade glioma (not otherwise specified)‡ | 0 | 1 (2) | 1 (1) |
| Recurrent disease, n (%) | 21 (53) | 17 (42) | 38 (47) |
| Anaplastic astrocytoma‡ | 3 (8) | 2 (5) | 5 (6) |
| Anaplastic ependymoma‡ | 1 (3) | 1 (2) | 2 (3) |
| Atypical meningioma | 1 (3) | 0 | 1 (1) |
| Glioblastoma‡ | 13 (33) | 14 (34) | 27 (33) |
| HGG (not otherwise specified)‡ | 2 (5) | 0 | 2 (3) |
| PNET | 1 (3) | 0 | 1 (1) |
| Unknown diagnosis, n (%) | 1 (3) | 1 (2) | 2 (3) |
| HGG (not otherwise specified)‡ | 1 (3) | 0 | 1 (1) |
| Pleomorphic xantoastrocytoma | 0 | 1 (2) | 1 (1) |
| Tumor location, n (%) | |||
| Supratentorial | 35 (88) | 36 (88) | 71 (88) |
| Infratentorial | 3 (8) | 1 (2) | 4 (5) |
| Unknown | 2 (5) | 4 (10) | 6 (7) |
*Where percentages are provided, they are for the total in the subgroup throughout (children or adolescents) and rounded to the nearest integer so may not equate to 100%.
†Austria, Germany, Israel, Italy, and Switzerland.
‡Considered HGGs.
EMEA, Europe, Middle East, and Africa; GBM, glioblastoma; HGG, high-grade glioma; PNET, primitive neuroectodermal tumor.